1
|
Noda Y, Soeda K, Uchida M, Goto S, Ito T, Kitagaki S, Mamiya T, Yoshimi A, Ozaki N, Mouri A. Multiple nicotinic acetylcholine receptor subtypes regulate social or cognitive behaviors in mice repeatedly administered phencyclidine. Behav Brain Res 2021; 408:113284. [PMID: 33819533 DOI: 10.1016/j.bbr.2021.113284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 02/21/2021] [Accepted: 03/30/2021] [Indexed: 11/15/2022]
Abstract
Habitual smoking in patients with schizophrenia (SCZ) is considered to improve their own psychoses or to develop a vulnerability to psychological dependence on (-)-nicotine ([-]-NIC) by stimulating nicotinic acetylcholine receptors (nAChRs) in the central nervous system. In the present study, we investigated whether habitual smoking is due to get therapeutic effect or to psychological dependence and which nAChR subunits are associated with them using mice that were repeatedly administered phencyclidine (PCP: 10 mg/kg/day, s.c. for 14 days) as SCZ-like model mice. Mice that were repeatedly administered PCP showed impairments in social or cognitive behaviors; decreased expression of α7 and/or α4 nAChR subunits in the prefrontal cortex (PFC); and increased expression of α7, α4, and β2 nAChR subunits in the nucleus accumbens (NAc). These changes were attenuated by repeated administration of (-)-NIC. The attenuating effects on behavioral impairments were prevented by a selective α7 nAChR antagonist and a selective α4β2 nAChR antagonist. At non- or weak effective dose by themselves, co-administration of (-)-NIC (0.03 mg/kg) and risperidone (0.03 mg/kg) showed synergistic effects on behavioral impairments in PCP-administered mice. Repeated (-)-NIC administration did not affect the performance of conditioned place preference, while it showed behavioral sensitization to (-)-NIC in the PCP-administered mice. Repeated (-)-NIC administration did not affect the performance of conditioned place preference, while it showed behavioral sensitization to (-)-NIC and attenuating effect on haloperidol-induced catalepsy in the PCP-administered mice. Our findings suggest that habitual smoking in SCZ might be attributed to get therapeutic and reduce side effects mediated by α7 and α4β2 nAChR activation by (-)-NIC.
Collapse
Affiliation(s)
- Yukihiro Noda
- Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty and Graduate School of Pharmacy, Nagoya, 468-8503, Japan.
| | - Koki Soeda
- Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty and Graduate School of Pharmacy, Nagoya, 468-8503, Japan
| | - Mizuki Uchida
- Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty and Graduate School of Pharmacy, Nagoya, 468-8503, Japan
| | - Sakika Goto
- Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty and Graduate School of Pharmacy, Nagoya, 468-8503, Japan
| | - Takahiro Ito
- Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty and Graduate School of Pharmacy, Nagoya, 468-8503, Japan
| | - Shinji Kitagaki
- Department of Medical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya, 468-8503, Japan
| | - Takayoshi Mamiya
- Department of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, 468-8503, Japan
| | - Akira Yoshimi
- Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty and Graduate School of Pharmacy, Nagoya, 468-8503, Japan
| | - Norio Ozaki
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8560, Japan
| | - Akihiro Mouri
- Department of Regulatory Science for Evaluation & Development of Pharmaceuticals and Devices, Graduate School of Health Science, Fujita Health University, Toyoake, 470-1192, Japan
| |
Collapse
|
2
|
Mesoy SM, Lummis SCR. M4, the Outermost Helix, is Extensively Involved in Opening of the α4β2 nACh Receptor. ACS Chem Neurosci 2021; 12:133-139. [PMID: 33295751 DOI: 10.1021/acschemneuro.0c00618] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Nicotinic acetylcholine receptors (nAChR) are the archetypal members of the pentameric ligand-gated ion channel (pLGIC) family, an important class of cell signaling proteins. In all members of this family, each of the five subunits has four transmembrane α-helices (M1-M4), with M2 lining the pore, then M1 and M3, and with M4 outermost and adjacent to the membrane lipids. Despite its remote location, M4 contributes both to receptor assembly and gating in pLGICs where it has been examined. This study probes the role of M4 residues in the α4β2 nAChR using site-directed mutagenesis to individually mutate each residue to alanine, followed by expression in HEK293 cells and then characterization using membrane potential sensitive dye and radioligand binding. Two of the resulting mutant receptors showed altered EC50s, while 13 were nonfunctional, although coexpression with the chaperones RIC3 and nAChO resulted in 4 of these responding to agonist. Of the remaining 9, radioligand binding with epibatidine showed that 8 were expressed, suggesting these residues may play a role in channel opening. These data differ from similar studies in other pLGIC, where few or no Ala mutants in M4 ablate function, and they suggest that the α4β2 nAChR M4 may play a more significant role than in related receptors.
Collapse
Affiliation(s)
- Susanne M. Mesoy
- Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB 1QW, United Kingdom
| | - Sarah C. R. Lummis
- Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB 1QW, United Kingdom
| |
Collapse
|
3
|
Neural circuits and nicotinic acetylcholine receptors mediate the cholinergic regulation of midbrain dopaminergic neurons and nicotine dependence. Acta Pharmacol Sin 2020; 41:1-9. [PMID: 31554960 PMCID: PMC7468330 DOI: 10.1038/s41401-019-0299-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Accepted: 08/06/2019] [Indexed: 12/23/2022] Open
Abstract
Midbrain dopaminergic (DA) neurons are governed by an endogenous cholinergic system, originated in the mesopontine nuclei. Nicotine hijacks nicotinic acetylcholine receptors (nAChRs) and interferes with physiological function of the cholinergic system. In this review, we describe the anatomical organization of the cholinergic system and the key nAChR subtypes mediating cholinergic regulation of DA transmission and nicotine reward and dependence, in an effort to identify potential targets for smoking intervention. Cholinergic modulation of midbrain DA systems relies on topographic organization of mesopontine cholinergic projections, and activation of nAChRs in midbrain DA neurons. Previous studies have revealed that α4, α6, and β2 subunit-containing nAChRs expressed in midbrain DA neurons and their terminals in the striatum regulate firings of midbrain DA neurons and activity-dependent dopamine release in the striatum. These nAChRs undergo modification upon chronic nicotine exposure. Clinical investigation has demonstrated that partial agonists of these receptors elevate the success rate of smoking cessation relative to placebo. However, further investigations are required to refine the drug targets to mitigate unpleasant side-effects.
Collapse
|
4
|
Pieschl RL, Miller R, Jones KM, Post-Munson DJ, Chen P, Newberry K, Benitex Y, Molski T, Morgan D, McDonald IM, Macor JE, Olson RE, Asaka Y, Digavalli S, Easton A, Herrington J, Westphal RS, Lodge NJ, Zaczek R, Bristow LJ, Li YW. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents. Eur J Pharmacol 2017; 807:1-11. [PMID: 28438647 DOI: 10.1016/j.ejphar.2017.04.024] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2016] [Revised: 04/13/2017] [Accepted: 04/19/2017] [Indexed: 10/19/2022]
Abstract
The α7 nicotinic acetylcholine receptor is thought to play an important role in human cognition. Here we describe the in vivo effects of BMS-902483, a selective potent α7 nicotinic acetylcholine receptor partial agonist, in relationship to α7 nicotinic acetylcholine receptor occupancy. BMS-902483 has low nanomolar affinity for rat and human α7 nicotinic acetylcholine receptors and elicits currents in cells expressing human or rat α7 nicotinic acetylcholine receptors that are about 60% of the maximal acetylcholine response. BMS-902483 improved 24h novel object recognition memory in mice with a minimal effective dose (MED) of 0.1mg/kg and reversed MK-801-induced deficits in a rat attentional set-shifting model of executive function with an MED of 3mg/kg. Enhancement of novel object recognition was blocked by the silent α7 nicotinic acetylcholine receptor agonist, NS6740, demonstrating that activity of BMS-902483 was mediated by α7 nicotinic acetylcholine receptors. BMS-902483 also reversed ketamine-induced deficits in auditory gating in rats, and enhanced ex vivo hippocampal long-term potentiation examined 24h after dosing in mice. Results from an ex vivo brain homogenate binding assay showed that α7 receptor occupancy ranged from 64% (novel object recognition) to ~90% (set shift and gating) at the MED for behavioral and sensory processing effects of BMS-902483.
Collapse
Affiliation(s)
- Rick L Pieschl
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Regina Miller
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Kelli M Jones
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Debra J Post-Munson
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Ping Chen
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Kimberly Newberry
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Yulia Benitex
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Thaddeus Molski
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Daniel Morgan
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Ivar M McDonald
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - John E Macor
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Richard E Olson
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Yukiko Asaka
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Siva Digavalli
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Amy Easton
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - James Herrington
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Ryan S Westphal
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Nicholas J Lodge
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Robert Zaczek
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Linda J Bristow
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Yu-Wen Li
- Bristol-Myers Squibb Company, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492, USA.
| |
Collapse
|
5
|
Zuo W, Xiao C, Gao M, Hopf FW, Krnjević K, McIntosh JM, Fu R, Wu J, Bekker A, Ye JH. Nicotine regulates activity of lateral habenula neurons via presynaptic and postsynaptic mechanisms. Sci Rep 2016; 6:32937. [PMID: 27596561 PMCID: PMC5011770 DOI: 10.1038/srep32937] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 08/12/2016] [Indexed: 11/09/2022] Open
Abstract
There is much interest in brain regions that drive nicotine intake in smokers. Interestingly, both the rewarding and aversive effects of nicotine are probably critical for sustaining nicotine addiction. The medial and lateral habenular (LHb) nuclei play important roles in processing aversion, and recent work has focused on the critical involvement of the LHb in encoding and responding to aversive stimuli. Several neurotransmitter systems are implicated in nicotine’s actions, but very little is known about how nicotinic acetylcholine receptors (nAChRs) regulate LHb activity. Here we report in brain slices that activation of nAChRs depolarizes LHb cells and robustly increases firing, and also potentiates glutamate release in LHb. These effects were blocked by selective antagonists of α6-containing (α6*) nAChRs, and were absent in α6*-nAChR knockout mice. In addition, nicotine activates GABAergic inputs to LHb via α4β2-nAChRs, at lower concentrations but with more rapid desensitization relative to α6*-nAChRs. These results demonstrate the existence of diverse functional nAChR subtypes at presynaptic and postsynaptic sites in LHb, through which nicotine could facilitate or inhibit LHb neuronal activity and thus contribute to nicotine aversion or reward.
Collapse
Affiliation(s)
- Wanhong Zuo
- Department of Anesthesiology, Pharmacology and Physiology, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, New Jersey, USA
| | - Cheng Xiao
- Department of Anesthesiology, Pharmacology and Physiology, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, New Jersey, USA
| | - Ming Gao
- Divisions of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA
| | - F Woodward Hopf
- Department of Neurology, University of California at San Francisco, CA, USA
| | | | - J Michael McIntosh
- George E. Wahlen Veterans Affairs Medical Center and Departments of Psychiatry and Biology, University of Utah, Salt Lake City, UT, USA
| | - Rao Fu
- Department of Anesthesiology, Pharmacology and Physiology, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, New Jersey, USA
| | - Jie Wu
- Divisions of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA
| | - Alex Bekker
- Department of Anesthesiology, Pharmacology and Physiology, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, New Jersey, USA
| | - Jiang-Hong Ye
- Department of Anesthesiology, Pharmacology and Physiology, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, New Jersey, USA
| |
Collapse
|
6
|
Tallarida CS, Tallarida RJ, Rawls SM. Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats. Drug Alcohol Depend 2015; 149:145-50. [PMID: 25683823 PMCID: PMC4447121 DOI: 10.1016/j.drugalcdep.2015.01.035] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Revised: 01/24/2015] [Accepted: 01/25/2015] [Indexed: 12/18/2022]
Abstract
BACKGROUND The Drug Enforcement Agency estimates that 80% of cocaine seized in the United States contains the veterinary pharmaceutical levamisole (LVM). One problem with LVM is that it is producing life-threatening neutropenia in an alarming number of cocaine abusers. The neuropharmacological profile of LVM is also suggestive of an agent with modest reinforcing and stimulant effects that could enhance cocaine's addictive effects. METHODS We tested the hypothesis that LVM (ip) enhances the rewarding and locomotor stimulant effects of cocaine (ip) using rat conditioned place preference (CPP) and locomotor assays. Effects of LVM by itself were also tested. RESULTS LVM (0-10 mg/kg) produced CPP at 1mg/kg (P<0.05) and locomotor activation at 5mg/kg (P < 0.05). For CPP combination experiments, a statistically inactive dose of LVM (0.1 mg/kg) was administered with a low dose of cocaine (2.5 mg/kg). Neither agent produced CPP compared to saline (P > 0.05); however, the combination of LVM and cocaine produced enhanced CPP compared to saline or either drug by itself (P < 0.01). For locomotor experiments, the same inactive dose of LVM (0.1mg/kg, ip) was administered with low (10 mg/kg) and high doses (30 mg/kg) of cocaine. LVM (0.1 mg/kg) enhanced locomotor activation produced by 10mg/kg of cocaine (P < 0.05) but not by 30 mg/kg (P>0.05). CONCLUSIONS LVM can enhance rewarding and locomotor-activating effects of low doses of cocaine in rats while possessing modest activity of its own.
Collapse
Affiliation(s)
- Christopher S Tallarida
- Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA
| | - Ronald J Tallarida
- Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA
| | - Scott M Rawls
- Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA.
| |
Collapse
|
7
|
Philip NS, Carpenter LL, Tyrka AR, Price LH. The nicotinic acetylcholine receptor as a target for antidepressant drug development. ScientificWorldJournal 2012; 2012:104105. [PMID: 22619570 PMCID: PMC3349306 DOI: 10.1100/2012/104105] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2012] [Accepted: 02/28/2012] [Indexed: 11/17/2022] Open
Abstract
An important new area of antidepressant drug development involves targeting the nicotinic acetylcholine receptor (nAChR). This receptor, which is distributed widely in regions of the brain associated with depression, is also implicated in other important processes that are relevant to depression, such as stress and inflammation. The two classes of drugs that target nAChRs can be broadly divided into mecamylamine- and cytisine-based compounds. These drugs probably exert their effects via antagonism at α4β2 nAChRs, and strong preclinical data support the antidepressant efficacy of both classes when used in conjunction with other primary antidepressants (e.g., monoamine reuptake inhibitors). Although clinical data remain limited, preliminary results in this area constitute a compelling argument for further evaluation of the nAChR as a target for future antidepressant drug development.
Collapse
Affiliation(s)
- Noah S Philip
- Mood Disorders Research Program, Butler Hospital and Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI 02906, USA. Philip, noah
| | | | | | | |
Collapse
|